September 16, 2020
1 min read

FDA approves Irish facility to produce Rhopressa for US market

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The FDA has approved Aerie Pharmaceuticals’ sterile fill facility in Athlone, Ireland, for the production of Rhopressa for commercial distribution in the U.S., according to a press release.

“What began as a vision to control our destiny from a manufacturing standpoint in 2015 has led to the FDA approval of our facility earlier this year to produce Rocklatan, and now Rhopressa, for commercial distribution in the United States,” Vicente Anido Jr., PhD, chairman and CEO of Aerie, said in the release.

Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution) shipments to the U.S. have begun, and Aerie is aiming to begin shipping Rhopressa (netarsudil ophthalmic solution 0.02%) to the U.S. later this year. The goal is to have the Athlone facility supply ophthalmic products for every market Aerie operates in, the release said.